子宫癌治疗和诊断市场 - 全球产业规模、份额、趋势、机会和预测，按癌症类型、治疗方法、诊断方法、地区和竞争细分，2020-2030 年预测

2024 年全球子宫癌治疗和诊断市场价值为 231 亿美元，预计在预测期内将出现令人印象深刻的增长，到 2030 年的复合年增长率为 5.75%。 子宫癌，也称为子宫内膜癌，是一种起源于子宫内膜的癌症。子宫是女性生殖器官，受精卵在怀孕期间在此着床，胎儿在此发育生长。当子宫内膜内异常细胞不受控制地生长时，就会发生子宫癌。子宫癌常表现为阴道异常出血、骨盆腔疼痛、排尿或排便习惯改变等症状。子宫癌的危险因子包括肥胖、荷尔蒙失衡、家族病史、林奇症候群等某些遗传疾病。子宫癌的诊断通常涉及病史评估、身体检查、影像学研究（如经阴道超音波、MRI 或 CT 扫描）和组织活检（通常透过子宫内膜活检或扩张和刮除术获得）。癌症分期有助于确定其扩散的程度并指导治疗决策。子宫癌的治疗因阶段、类型和个别患者因素而异，但通常包括手术（如子宫切除术）、放射疗法、化学疗法、标靶疗法，以及在某些情况下的免疫疗法。早期发现和及时治疗可以为许多子宫癌患者带来良好的治疗效果。改良的诊断技术，包括 MRI 和 CT 扫描等影像方式以及分子和基因检测，使得能够更早、更准确地诊断子宫癌。持续的研究和开发努力推动了子宫癌治疗的创新。这包括标靶疗法、免疫疗法和新型化疗药物的开发。人口老化，特别是已开发国家的人口老化，导致子宫癌发生率上升。老年人罹患此类癌症的风险更高。

主要市场驱动因素

老年人口不断增加

主要市场挑战

合併症和多学科护理

主要市场趋势

精准医疗

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：全球子宫癌治疗与诊断市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依癌症类型（子宫内膜腺癌、腺鳞癌、乳头状浆液性癌、子宫肉瘤）
  • 依治疗方法（手术、免疫疗法、放射线治疗、化学疗法、其他）
  • 透过诊断（活检、骨盆超音波检查、子宫腔镜检查、扩张和刮除术、CT 扫描）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 6 章：亚太地区子宫癌治疗与诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 7 章：欧洲子宫癌治疗与诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 8 章：北美子宫癌治疗与诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 9 章：南美洲子宫癌治疗与诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲子宫癌治疗和诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 13 章：全球子宫癌治疗与诊断市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章： 大环境分析

第 16 章：竞争格局

• Ariad Pharmaceuticals, Inc.
• Abbott Laboratories Inc.
• Becton, Dickinson & Co.
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• Siemens Healthineers AG.
• F. Hoffmann-La Roche AG

第 17 章：策略建议

第18章 调査会社について・免责事项

Global Uterine Cancer Therapeutics & Diagnostics Market was valued at USD 23.10 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.75% through 2030. Uterine cancer, also known as endometrial cancer, is a type of cancer that originates in the lining of the uterus, called the endometrium. The uterus is a female reproductive organ where a fertilized egg implants and a developing fetus grows during pregnancy. Uterine cancer occurs when there is uncontrolled growth of abnormal cells within the endometrial lining. Uterine cancer often presents with symptoms such as abnormal vaginal bleeding, pelvic pain, and changes in urinary or bowel habits. The risk factors for uterine cancer include obesity, hormone imbalances, a family history of the disease, and certain genetic conditions like Lynch syndrome. Diagnosis of uterine cancer typically involves a combination of medical history evaluation, physical examination, imaging studies (such as transvaginal ultrasound, MRI, or CT scans), and tissue biopsy (usually obtained through endometrial biopsy or dilation and curettage). Staging of the cancer helps determine the extent of its spread and guides treatment decisions. Treatment for uterine cancer varies depending on the stage, type, and individual patient factors but often includes surgery (such as hysterectomy), radiation therapy, chemotherapy, targeted therapy, and, in some cases, immunotherapy. Early detection and timely treatment can lead to favorable outcomes for many uterine cancer patients. Improved diagnostic techniques, including imaging modalities like MRI and CT scans, as well as molecular and genetic testing, enabled earlier and more accurate diagnosis of uterine cancer. Ongoing research and development efforts led to innovations in uterine cancer therapeutics. This included the development of targeted therapies, immunotherapies, and novel chemotherapeutic agents. The aging population, particularly in developed nations, contributed to a higher prevalence of uterine cancer. Older individuals are at higher risk for this type of cancer.

Key Market Drivers

Rising Geriatric Population

The rising geriatric population is a key driver fueling the growth of the global uterine cancer therapeutics & diagnostics market. The global population aged 65 and older is expected to more than double, increasing from 761 million in 2021 to 1.6 billion by 2050. The 80+ demographic is expanding at an even faster rate. This irreversible demographic shift is set to reshape industries, drive demand for age-specific healthcare solutions, and create new market opportunities across pharmaceuticals, medical diagnostics, elderly care services, and insurance sectors. As the global population ages, the prevalence of uterine cancer-particularly endometrial cancer-has increased, leading to a higher demand for advanced diagnostics, innovative treatments, and specialized healthcare services. Below is a detailed analysis of how the aging demographic is shaping this market. Uterine cancer is more common among postmenopausal women, with the majority of cases diagnosed in women aged 50 and above. Endometrial cancer (EC) ranks as the sixth most prevalent cancer among women globally, with its incidence surging significantly over the past two decades. In 2019 alone, 435,041 new cases were diagnosed, resulting in 91,641 fatalities worldwide. This sharp rise underscores the growing burden on healthcare systems, accelerating demand for advanced diagnostics, targeted therapies, and innovative treatment solutions in the oncology market. As global life expectancy increases, the number of elderly women at risk also grows, leading to a direct rise in demand for cancer diagnostics and therapeutics. With an aging population, healthcare providers are prioritizing early detection and preventive screening programs to manage uterine cancer effectively. Governments and healthcare organizations are actively investing in: Routine gynecological screenings for older women, Biomarker-based diagnostic tests to detect cancer in early stages, AI-driven imaging solutions (MRI, PET scans) for precise detection. This increasing emphasis on early diagnosis and regular screenings is driving the market for diagnostic devices, pathology services, and molecular testing kits.

Key Market Challenges

Comorbidities and Multidisciplinary Care

Many uterine cancer patients have comorbid conditions, such as diabetes, hypertension, heart disease, or obesity. Managing uterine cancer alongside these comorbidities can complicate treatment decisions. Healthcare providers must weigh the benefits of aggressive cancer treatment against the potential risks and interactions with existing health conditions and medications. Comorbidities can affect a patient's ability to tolerate cancer treatments, such as surgery, chemotherapy, or radiation therapy. For example, individuals with heart disease may be at increased risk during surgery or may not tolerate certain chemotherapy regimens. Patients with multiple health conditions often take multiple medications. The potential for drug interactions between cancer therapies and medications for comorbidities must be carefully managed to avoid adverse effects. Due to the complexity of managing uterine cancer in patients with comorbidities, a multidisciplinary approach involving oncologists, surgeons, cardiologists, endocrinologists, and other specialists is often necessary. Coordinating care and communication among these specialists can be challenging. Each patient's case is unique, requiring individualized treatment plans that consider both the cancer and comorbidities. This necessitates close collaboration among healthcare providers. Determining the optimal sequencing of cancer treatments and interventions for comorbidities is crucial. For example, deciding whether to address heart disease or uterine cancer first can impact treatment outcomes.

Key Market Trends

Precision Medicine

Advances in genetic testing allowed for the comprehensive profiling of uterine cancer tumors. This profiling identified specific genetic mutations and alterations that drive cancer growth. Oncologists could use this information to select targeted therapies that were more likely to be effective for individual patients. Researchers were identifying and validating specific biomarkers associated with uterine cancer. These biomarkers could be used for early detection, prognosis assessment, and treatment decision-making. Precision medicine guided treatment decisions based on the molecular characteristics of a patient's tumor. This approach minimized the use of one-size-fits-all treatments and aimed to improve treatment efficacy while reducing side effects. Immunotherapy drugs, which stimulate the patient's immune system to target cancer cells, were being explored as part of precision medicine approaches for uterine cancer. Some patients with specific molecular profiles responded well to immunotherapy. Precision medicine was driving the design of clinical trials that focused on specific genetic subtypes of uterine cancer. These trials aimed to test new therapies and treatment combinations tailored to the molecular profiles of patients. Precision medicine also played a role in assessing a patient's risk of developing uterine cancer based on their genetic and environmental factors. This could inform prevention and early detection strategies.

Regional Insights

The North America region was the largest market in the Global Uterine Cancer Therapeutics & Diagnostics Market in 2024. North America, particularly the United States, has one of the highest healthcare spending rates in the world. This substantial investment in healthcare infrastructure and research and development contributes to advancements in uterine cancer therapeutics and diagnostics. The region boasts advanced healthcare facilities, medical technology, and a well-developed healthcare system. This allows for early detection, accurate diagnosis, and state-of-the-art treatment options for uterine cancer patients. North America is home to numerous pharmaceutical and biotechnology companies that invest heavily in cancer research, including uterine cancer. These companies develop innovative therapeutics and diagnostic tools for the market. The United States hosts a large number of clinical trials for various cancer types, including uterine cancer. Clinical trials are critical for testing new treatments and diagnostic methods, attracting patients from around the world.

Key Market Players

• Ariad Pharmaceuticals, Inc.
• Abbott Laboratories Inc.
• Becton, Dickinson & Co.
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• Siemens Healthineers AG.
• F. Hoffmann-La Roche AG

Report Scope:

In this report, the Global Uterine Cancer Therapeutics & Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Uterine Cancer Therapeutics & Diagnostics Market, By Cancer Type:

• Endometrial Adenocarcinoma
• Adenosquamous Carcinoma
• Papillary Serous Carcinoma
• Uterine Sarcoma

Uterine Cancer Therapeutics & Diagnostics Market, By Therapeutics:

• Surgery
• Immunotherapy
• Radiation Therapy
• Chemotherapy
• Others

Uterine Cancer Therapeutics & Diagnostics Market, By Diagnostics:

• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• Dilation and Curettage
• CT scan

Uterine Cancer Therapeutics & Diagnostics Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Uterine Cancer Therapeutics & Diagnostics Market.

Available Customizations:

Global Uterine Cancer Therapeutics & Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma)
  • 5.2.2. By Therapeutics (Surgery, Immunotherapy, Radiation Therapy, Chemotherapy, Others)
  • 5.2.3. By Diagnostics (Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage, CT scan)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Therapeutics
  • 6.2.3. By Diagnostics
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Therapeutics
      • 6.3.1.2.3. By Diagnostics
  • 6.3.2. India Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Therapeutics
      • 6.3.2.2.3. By Diagnostics
  • 6.3.3. Australia Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Therapeutics
      • 6.3.3.2.3. By Diagnostics
  • 6.3.4. Japan Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Cancer Type
      • 6.3.4.2.2. By Therapeutics
      • 6.3.4.2.3. By Diagnostics
  • 6.3.5. South Korea Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Cancer Type
      • 6.3.5.2.2. By Therapeutics
      • 6.3.5.2.3. By Diagnostics

7. Europe Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Therapeutics
  • 7.2.3. By Diagnostics
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Therapeutics
      • 7.3.1.2.3. By Diagnostics
  • 7.3.2. Germany Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Therapeutics
      • 7.3.2.2.3. By Diagnostics
  • 7.3.3. Spain Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Therapeutics
      • 7.3.3.2.3. By Diagnostics
  • 7.3.4. Italy Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Type
      • 7.3.4.2.2. By Therapeutics
      • 7.3.4.2.3. By Diagnostics
  • 7.3.5. United Kingdom Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Type
      • 7.3.5.2.2. By Therapeutics
      • 7.3.5.2.3. By Diagnostics

8. North America Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Therapeutics
  • 8.2.3. By Diagnostics
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Therapeutics
      • 8.3.1.2.3. By Diagnostics
  • 8.3.2. Mexico Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Therapeutics
      • 8.3.2.2.3. By Diagnostics
  • 8.3.3. Canada Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Therapeutics
      • 8.3.3.2.3. By Diagnostics

9. South America Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Therapeutics
  • 9.2.3. By Diagnostics
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Therapeutics
      • 9.3.1.2.3. By Diagnostics
  • 9.3.2. Argentina Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Therapeutics
      • 9.3.2.2.3. By Diagnostics
  • 9.3.3. Colombia Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Therapeutics
      • 9.3.3.2.3. By Diagnostics

10. Middle East and Africa Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Type
  • 10.2.2. By Therapeutics
  • 10.2.3. By Diagnostics
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Type
      • 10.3.1.2.2. By Therapeutics
      • 10.3.1.2.3. By Diagnostics
  • 10.3.2. Saudi Arabia Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Type
      • 10.3.2.2.2. By Therapeutics
      • 10.3.2.2.3. By Diagnostics
  • 10.3.3. UAE Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Type
      • 10.3.3.2.2. By Therapeutics
      • 10.3.3.2.3. By Diagnostics

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Uterine Cancer Therapeutics & Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Ariad Pharmaceuticals, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Product & Service Offerings
  • 16.1.3. Recent Developments
  • 16.1.4. Financials (If Listed)
  • 16.1.5. Key Personnel
  • 16.1.6. SWOT Analysis
• 16.2. Abbott Laboratories Inc.
• 16.3. Becton, Dickinson & Co.
• 16.4. GlaxoSmithKline Plc
• 16.5. Merck & Co., Inc.
• 16.6. Novartis AG
• 16.7. Sanofi SA
• 16.8. Siemens Healthineers AG.
• 16.9. F. Hoffmann-La Roche AG

17. Strategic Recommendations

18. About Us & Disclaimer